Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development
Benzinga Newsdesk 3 weeks ago
News
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx plans
- Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)
- First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease
- argenx plans to advance FB102 into Phase 3 development